ADIL -
Adial Pharmaceuticals, Inc
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 0.32 -0.03 (-7.89%) |
--- |
0.0 (0.0%) |
0.0 (-1.36%) |
-0.03 (-10.22%) |
0.01 (2.59%) |
0.0 (-0.52%) |
-0.02 (-6.45%) |
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
Earnings & Ratios
- Basic EPS:
- -0.34
- Diluted EPS:
- -0.34
- Basic P/E:
- -0.875
- Diluted P/E:
- -0.875
- RSI(14) 1m:
- 78.12
- VWAP:
- 0.3
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
Oct 17, 2025 13:00
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight
Apr 28, 2025 17:00
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
Feb 25, 2025 14:00
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Jan 29, 2025 14:00
Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight
Dec 11, 2024 18:00
EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder - Benzinga
Jul 23, 2024 12:00
Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder
Jun 20, 2024 12:30
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024 12:30
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
Apr 22, 2024 12:30
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Apr 15, 2024 18:11